Jeena Sikho Lifecare Limited (JSLL), a leading Ayurvedic healthcare provider, has reported robust financial results for the second quarter, showcasing significant growth across key metrics.

Financial Highlights

JSLL delivered impressive quarterly results, with net profit soaring to ₹588.00 million from ₹266.00 million year-over-year, marking a substantial 121% increase. The company's revenue grew significantly to ₹1,898.50 million, up from ₹1,140.90 million in the same period last year, representing a 67% growth.

Operational Performance

The company's EBITDA more than doubled to ₹920.60 million from ₹402.70 million year-over-year. Notably, JSLL's EBITDA margin expanded substantially to 48.49% from 35.30% in the previous year, indicating improved operational efficiency and profitability.

Key Performance Indicators

Operational Expansion

JSLL continues to expand its operational footprint. The company reported that three new hospitals became operational during the quarter, increasing the total operational bed capacity to over 2,220 beds. Additionally, approximately 400 beds are currently under development across five facilities.

Strategic Focus

The company has been strategically shifting its focus towards the private business segment, which offers superior margins compared to the Government Panel segment. This shift in business mix is expected to further strengthen profitability and improve the overall cash-conversion cycle.

Product Portfolio Expansion

JSLL's OTC and Medicines division continues to deliver strong performance, supported by the launch of new products such as Dr. BP Care DS, Dr. Kidney Care DS, Dr. Madhu Care DS, Dr. Liver DS, and Dr. Sukoon DS. These products have been well-received in the market, driving consistent growth in product revenues.

Technology Integration

JSLL has entered into a strategic partnership with Salesforce, a globally recognized leader in cloud-based enterprise solutions. This collaboration is expected to significantly elevate the quality of patient care and operational efficiency.

Management Commentary

Acharya Manish Ji, Managing Director of JSLL, commented on the results, stating, "Jeena Sikho continued to maintain strong business momentum during the first half of the financial year. Our strategic initiatives and consistent operational excellence have resulted in robust growth for H1 FY26 compared to the previous financial year."

He further added, "Our expansion initiatives remained on track during the quarter, and the enhanced utilization of existing capacity has further improved operational efficiency and contributed positively to margin expansion."

The company's strong performance and strategic initiatives position it well for continued growth in the Ayurvedic healthcare sector.

Jeena Sikho Lifecare Limited (JSLL) has made a significant move in the Ayurvedic wellness sector with the national launch of its Pet Shuddhi product line. The company, known for its focus on Ayurvedic treatments and wellness solutions, introduced the Pet-Yakrit-Pleeha Shuddhi Kit during a press conference held in New Delhi on October 13, 2025.

Product Details

The Pet-Yakrit-Pleeha Shuddhi Kit is an Ayurvedic detox product designed to cleanse and strengthen three vital organs:

1. Stomach
2. Liver
3. Spleen

This specially formulated kit aims to promote complete detoxification, helping the body maintain balance, energy, and overall health. According to the company, the product is particularly beneficial for conditions such as:

• Gas
• Indigestion
• Constipation
• Obesity
• Liver weakness

Nationwide Availability

JSLL has made the Pet-Yakrit-Pleeha Shuddhi Kit available across India through its Jeena Sikho Hospitals Network. This move marks a significant expansion of the company's product reach and accessibility to consumers nationwide.

Market Impact

The launch of the Pet-Yakrit-Pleeha Shuddhi Kit has garnered substantial attention from both the media and the public. The event received coverage across leading newspapers and news channels, indicating strong interest in Ayurvedic wellness solutions.

Corporate Developments

In addition to the product launch, JSLL has entered into an exclusive diagnostic collaboration agreement with Chandan Healthcare Limited. This strategic partnership aims to enhance JSLL's healthcare offerings by integrating diagnostic and preventive healthcare services within its network.

Key points of the collaboration include:

• Chandan Healthcare appointed as the exclusive diagnostic partner for all Jeena Sikho hospitals, clinics, and wellness centers
• Five-year lock-in period for the collaboration
• Establishment of diagnostic centers within JSLL premises by Chandan Healthcare
• Integration of "Chandan Healthcare Cards" for patient access

This partnership is expected to improve patient experience and strengthen JSLL's position as a comprehensive healthcare and wellness service provider.

Financial Perspective

As of the latest available data, Jeena Sikho Lifecare Limited's market capitalization stands at ₹9,183.96 crore, while Chandan Healthcare Limited's market capitalization is ₹762.66 crore. This collaboration between the two companies represents a significant strategic move in the healthcare sector, potentially impacting their market positions and service offerings.

The launch of the Pet-Yakrit-Pleeha Shuddhi Kit, coupled with the strategic partnership with Chandan Healthcare, demonstrates JSLL's commitment to expanding its product portfolio and enhancing its healthcare services. These developments could potentially drive growth and increase market share for JSLL in the competitive Ayurvedic wellness and healthcare sectors.